Birol OCAK, Ahmet Bilgehan SAHIN, Bahar DAKİKİ, Hikmet Utku ODMAN, Sibel Oyucu ORHAN, Adem DELIGONUL, Hüseyin MELEK, Erdem ÇUBUKÇU, Turkkan EVRENSEL

The benefit of surgery on survival for patients with stage 1 and 2 malignant pleural mesothelioma

Objective: Malignant mesothelioma is a rare and aggressive cancer. We aim to report our experience of stage 1 and 2 malign pleural mesothelioma (MPM) and investigate the prognostic factors.Methods: We retrospectively reviewed 37 patients with clinical stage 1 and 2 MPM in our center and examined radiological findings, demographic characteristics, treatment modalities, survival, and recurrence.Results: Eighteen of the 37 patients were male, and the mean age of the patients was 59.0 ± 11.2 years. Thirty patients had stage 1 MPM, and 7 patients had stage 2. Seven patients underwent surgery, and 30 patients received induction chemotherapy. Median progression-free survival (PFS) was 12.3 months (95% confidence interval [CI], 9.4-15.1), and the median overall survival (OS) was 24.3 months (95% CI, 15.8-32.8). In multivariate analysis, while gender and surgery had a statistically significant effect on PFS (p=0.01, p=0.01, respectively), both gender and surgery did not significantly affect OS (p=0.15, p=0.08, respectively). Local recurrence occurred in 28 patients, and 7 patients were presented with local recurrence and distant metastasis.Conclusion: In our study, where the majority of patients were stage 1 and 2, the effect of the surgery was significant.

Evre 1-2 Malign Plevral Mezotelyoma Hastalarında Sağkalıma Cerrahinin Katkısı

Amaç: Malign plevral mezotelyoma nadir görülen, agresif seyirli bir kanserdir. Bu çalışmamızda, evre1-2 malign plevral mezotelyomada prognostik faktörleri araştırmayı ve deneyimlerimizi sunmayı amaçladık. Yöntemler: Merkezimizde evre 1 ve 2 MPM olan 37 hastanın radyolojik bulgularını, demografik özelliklerini, tedavi yöntemlerini, sağkalımını ve nüksünü retrospektif olarak inceledik. Bulgular: 37 hastanın 18'i erkekti ve hastaların yaş ortalaması 59,0 ± 11,2 yıldı. Evre-1 30 hasta, evre-2 7 hasta vardı. 7 hasta opere oldu, 30 hasta ise indüksiyon kemoterapisi aldı. Medyan progresyonsuz sağkalım 12,3 ay (%95 CI, 9,4-15,1) ve medyan genel sağ kalım 24,3 ay (%95 CI, 15,8-32,8) olarak bulundu. Çok değişkenli analizde, cinsiyet ve cerrahinin hastalıksız sağ kalım üzerinde istatistiksel olarak anlamlı etkisi saptanırken (sırasıyla p= 0,01, p= 0,01), hem cinsiyet hem de cerrahi genel sağ kalımı anlamlı olarak etkilemedi (sırasıyla p=0,15, p=0,08). 28 hastada lokal nüks, 7 hastada lokal nüks ve uzak metastaz saptandı. Sonuç: Cerrahinin etkisi, evre 1-2 hastaların çoğunlukta olduğu çalışmamızda anlamlı olarak bulundu.

PDF

___

1.Hiriart E, Deepe R, Wessels A. Mesothelium andMalignant Mesothelioma. J Dev Biol. 2019; 7.

2.Ali G, Bruno R, Fontanini G. The pathological andmolecular diagnosis of malignant pleuralmesothelioma: a literature review. J Thorac Dis.2018; 10: 276-84.

3.Akdeniz N, Küçüköner M, Kaplan MA, et al. TheEffect of Metabolic PET Parameters on SurvivalOutcome in Malignant Pleural Mesothelioma. DicleTıp Dergisi. 2020; 47: 16-23.

4.Perikleous P, Waller DA. Video assistedthoracoscopic and open chest surgery in diagnosisand treatment of malignant pleural diseases. J VisSurg. 2017;3:85.

5.National Comprehensive Cancer Network.Malignant Pleural Mesothelioma (Version 1.2020).[https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf]. (Access date: 05/03/2020).

6.Weder W, Stahel RA, Bernhard J, et al. Multicentertrial of neo-adjuvant chemotherapy followed byextrapleural pneumonectomy in malignant pleuralmesothelioma. Ann Oncol. 2007; 18: 1196-202.

7.Krug LM, Pass HI, Rusch VW, et al. Multicenterphase II trial of neoadjuvantpemetrexed pluscisplatin followed by extrapleural pneumonectomyand radiation for malignant pleural mesothelioma. JClinOncol. 2009; 27: 3007-13.

8.Datta A, Smith R, Fiorentino F, Treasure T. Surgeryin the treatment of malignant pleural mesothelioma: recruitment into trials should be the defaultposition. Thorax. 2014; 69: 194-7.

9.Taioli E, Wolf AS, Camacho-Rivera M, Flores RM.Women with malignant pleural mesothelioma havea threefold better survival rate than men. AnnThorac Surg. 2014; 98:1020-4.

10.Espinoza MF, Berz D, Borgella JD, Imai TA,Soukiasian HJ. Neoadjuvant versus adjuvantchemotherapy for resectable malignant pleuralmesothelioma: An analysis of the National CancerDatabase. In.: American Society of Clinical Oncology;2018.

11.Voigt SL, Raman V, Jawitz OK, et al. The Role ofNeoadjuvant Chemotherapy in Patients withResectable Malignant Pleural Mesothelioma - AnInstitutional and National Analysis. J Natl Cancer Inst. 2020.

12.Sugarbaker DJ, Gill RR, Yeap BY, et al.Hyperthermic intraoperative pleural cisplatinchemotherapy extends interval to recurrence andsurvival among low-risk patients with malignantpleural mesothelioma undergoing surgicalmacroscopic complete resection. JThoracCardiovasc Surg. 2013; 145: 955-63.

13.Gomez DR, Rimner A, Simone CB, et al. The Useof Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from theNational Cancer Institute Thoracic MalignancySteering Committee, International Association forthe Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J ThoracOncol. 2019; 14:1172-83.